PURPOSE: The present study was designed to determine whether the nuclear or cytoplasmic expression of survivin, was related to clinicopathological parameters and survival in sporadic colon carcinomas. METHODS: Western blotting of cell fractions and immunocytochemical methodology were used in five human colon cancer cell lines. Immunohistochemical study was performed in formalin-fixed paraffin-embedded section from 46 patients with sporadic colorectal adenocarcinomas with a polyclonal antibody directed against survivin. Apoptotic index was evaluated by using the M30 antibody. Survival rates were estimated by the Kaplan-Meier method and compared using the log-rank test. Multivariate survival analysis was performed by the Cox proportional hazards model. RESULTS: Western blotting and immunocytochemistry analyses confirmed that survivin could be detected both in the nucleus and the cytoplasm. Immunohistochemical analysis demonstrated that 39% of tumours expressed survivin in the nucleus and 41% in the cytoplasm. No relationship was observed between survivin expression and clinicopathological features. Unexpectedly, the apoptotic index appeared to be linked with high survivin nuclear expression. Overall, 3-year observed survival rate was 73% in patients with cytoplasmic survivin expression versus 48% for negative expression (P = 0.14). Survival was 72% versus 50% for positive nuclear survivin expression versus negative (P = 0.16). After adjustment for age and stage, cytoplasmic survivin expression was a significant prognostic factor. A high level of expression was associated to a better survival: RR = 0.35 [0.13-0.98], P = 0.045. CONCLUSION: These results indicate that the analysis of the subcellular expression of survivin is a determining factor to define the prognostic value. Its evaluation, using a polyclonal antibody, might help clinicians in the stratification of patients with colorectal cancer.
PURPOSE: The present study was designed to determine whether the nuclear or cytoplasmic expression of survivin, was related to clinicopathological parameters and survival in sporadic colon carcinomas. METHODS: Western blotting of cell fractions and immunocytochemical methodology were used in five humancolon cancer cell lines. Immunohistochemical study was performed in formalin-fixed paraffin-embedded section from 46 patients with sporadic colorectal adenocarcinomas with a polyclonal antibody directed against survivin. Apoptotic index was evaluated by using the M30 antibody. Survival rates were estimated by the Kaplan-Meier method and compared using the log-rank test. Multivariate survival analysis was performed by the Cox proportional hazards model. RESULTS: Western blotting and immunocytochemistry analyses confirmed that survivin could be detected both in the nucleus and the cytoplasm. Immunohistochemical analysis demonstrated that 39% of tumours expressed survivin in the nucleus and 41% in the cytoplasm. No relationship was observed between survivin expression and clinicopathological features. Unexpectedly, the apoptotic index appeared to be linked with high survivin nuclear expression. Overall, 3-year observed survival rate was 73% in patients with cytoplasmic survivin expression versus 48% for negative expression (P = 0.14). Survival was 72% versus 50% for positive nuclear survivin expression versus negative (P = 0.16). After adjustment for age and stage, cytoplasmic survivin expression was a significant prognostic factor. A high level of expression was associated to a better survival: RR = 0.35 [0.13-0.98], P = 0.045. CONCLUSION: These results indicate that the analysis of the subcellular expression of survivin is a determining factor to define the prognostic value. Its evaluation, using a polyclonal antibody, might help clinicians in the stratification of patients with colorectal cancer.
Authors: C Adida; C Haioun; P Gaulard; E Lepage; P Morel; J Briere; H Dombret; F Reyes; J Diebold; C Gisselbrecht; G Salles; D C Altieri; T J Molina Journal: Blood Date: 2000-09-01 Impact factor: 22.113
Authors: A Krieg; C Mahotka; T Krieg; H Grabsch; W Müller; S Takeno; C V Suschek; M Heydthausen; H E Gabbert; C D Gerharz Journal: Br J Cancer Date: 2002-03-04 Impact factor: 7.640
Authors: Dermot T McDowell; Fraser M Smith; John V Reynolds; Stephen G Maher; Collette Adida; Paul Crotty; Eoin F Gaffney; Donal Hollywood; Brian Mehigan; Richard B Stephens; M J Kennedy Journal: Int J Colorectal Dis Date: 2009-07-11 Impact factor: 2.571
Authors: Jonathan M Hernandez; Jeffrey M Farma; Domenico Coppola; Ardeshir Hakam; William J Fulp; Dung-Tsa Chen; Erin M Siegel; Timothy J Yeatman; David Shibata Journal: Clin Colorectal Cancer Date: 2011-04-28 Impact factor: 4.481
Authors: Katarzyna Jakubowska; Anna Pryczynicz; Violetta Dymicka-Piekarska; Waldemar Famulski; Katarzyna Guzińska-Ustymowicz Journal: Oncol Lett Date: 2016-09-01 Impact factor: 2.967
Authors: Peter C Konturek; Kazimierz Rembiasz; Grzegorz Burnat; Stanisław J Konturek; Marcin Tusinela; Władysław Bielanski; Jens Rehfeld; Danuta Karcz; Eckhart Hahn Journal: Dig Dis Sci Date: 2006-04 Impact factor: 3.199
Authors: Y J Fang; Z H Lu; G Q Wang; Z Z Pan; Z W Zhou; J P Yun; M F Zhang; D S Wan Journal: Int J Colorectal Dis Date: 2009-05-07 Impact factor: 2.571
Authors: Maria Teresa Ionta; Maria Teresa Perra; Francesco Atzori; Cristina Maxia; Valeria Pusceddu; Paolo Demurtas; Maria Cristina Deidda; Franca Piras; Barbara Frau; Daniela Murtas; Luigi Minerba; Bruno Massidda; Paola Sirigu Journal: Exp Ther Med Date: 2010-01-01 Impact factor: 2.447